<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="996">
  <stage>Registered</stage>
  <submitdate>25/11/2005</submitdate>
  <approvaldate>25/11/2005</approvaldate>
  <nctid>NCT00259064</nctid>
  <trial_identification>
    <studytitle>Iressa v BSC (Best Supportive Care) in First Line NSCLC</studytitle>
    <scientifictitle>A Phase II Multicentre Randomised, Parallel Group, Double-Blind, Placebo-Controlled Study of ZD1839 (IRESSATM) (250MG Tablet) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Chemotherapy-Naive Patients With Advanced (Stage IIIB or IV) Non-Small Cell Lung Cancer (NSCLC) and Poor Performance Status</scientifictitle>
    <utrn />
    <trialacronym>INSTEP</trialacronym>
    <secondaryid>D7913C00711</secondaryid>
    <secondaryid>1839IL/0711</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>NSCLC</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Gefitinib
Other interventions - Placebo

Experimental: Gefitinib - ZD1839 + BSC (best supportive care)

Placebo Comparator: Placebo - Placebo + BSC (best supportive care)


Treatment: drugs: Gefitinib


Other interventions: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To compare Iressa v best supportive care in terms of progression free survival</outcome>
      <timepoint>Progression-free survival</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To compare Iressa v best supportive care in terms of objective tumour response rate</outcome>
      <timepoint>Overall objective tumour response rate (CR and PR) according to the RECIST criteria</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare Iressa v best supportive care in terms of overall survival</outcome>
      <timepoint>Time to death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare Iressa v best supportive care in terms of quality of life</outcome>
      <timepoint>Improvement in patient-reported functionality as measured by trial outcome index, comprised of the physical and functional well being sections and LCS of FACT-L and quality of life measured by the FACT-L total score</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To compare Iressa v best supportive care in terms of tolerability</outcome>
      <timepoint>Adverse event profile (type, frequency and severity of adverse events); laboratory parameters and vital signs</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Histologically or cytologically confirmed NSCLC

          -  NSCLC - locally advanced (Stage IIIB) or metastatic (stage IV) disease, not amenable
             to curative surgery or radiotherapy

          -  Not suitable for chemotherapy

          -  WHO Performance status 2 or 3</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>130</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Newly diagnosed CNS mets

          -  Less than 4 weeks since completion of radiotherapy or persistence of any radiotherapy
             related toxicity

          -  Other co-existing malignancies

          -  ALT/AST greater than 5 x upper limit of normal

          -  ANC less than 1.0 x 109/L or platelets less than 100 x 109/L</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>216</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Research Site - Bedford Park</hospital>
    <hospital>Research Site - Chermside</hospital>
    <hospital>Research Site - Concord</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Newcastle</hospital>
    <hospital>Research Site - Prahran</hospital>
    <hospital>Research Site - Randwick</hospital>
    <postcode> - Bedford Park</postcode>
    <postcode> - Chermside</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - Prahran</postcode>
    <postcode> - Randwick</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>New Brunswick</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Nova Ves pod Plesi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Den Bosch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Den Haag</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zutphen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Abergavenny</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cardiff</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wolverhampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine if the addition of Iressa to Best Supportive Care
      treatment will increase the progression free survival of chemo-na√Øve, poor performance status
      patients, with stage IIIB or IV NSCLC.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00259064</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca Iressa Medical Science Director, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>